Lived experience matters — and it stays clearly labeled so it is never mistaken for clinical proof.
One of the largest T1D communities in the world. Scott Benner (dad of a T1D daughter) interviews people with T1D, parents, and clinicians — focused on practical diabetes management, Bold with Insulin, and the real-life nuances of living with T1D.
VisitGlobal nonprofit co-founded by Nick Jonas. Covers T1D advocacy, management, community stories, clinical trial access, and the T1D Tech Summit. One of the most active social communities for people with T1D.
VisitThe world's leading T1D research funder (formerly JDRF). Funds cure programs, clinical trials, and advocacy. Their YouTube and TikTok channels surface breakthroughs, trial updates, and researcher interviews.
VisitA nutrition-focused education platform by two certified diabetes care educators who both live with T1D. They teach a low-fat, plant-based approach and have trained thousands of people to reduce insulin resistance. Note: their dietary approach is evidence-informed but not universally recommended — labeled as community/education, not clinical guidance.
VisitIndependent diabetes news and advocacy organization. Covers research, devices, policy, and living well with diabetes. Run by the diaTribe Foundation with journalists who live with or alongside diabetes.
VisitA nonprofit research organization running the largest T1D patient registry in the US. Their Glu community platform and Quality Improvement Collaborative drive real-world outcomes data and improvements in clinical care.
VisitLong-running online community for parents of children with T1D and adults with T1D. Hosts Friends for Life conferences, technology forums, and a large Q&A archive.
VisitLeading T1D cell-replacement therapy developer. Programs VX-880 (zimislecel, stem cell-derived islets with immunosuppression) and VX-264 (encapsulated islets, immunosuppression-free) are among the most advanced cure-track programs in the world.
WebsiteEngineering hypoimmune (immune-evasive) cells designed to avoid rejection without chronic immunosuppression. UP421 and SC451 are their T1D programs. Early human data has been reported.
WebsiteDeveloping the Cell Pouch — an implantable device that grows its own blood supply for donor islet cells. Partners with Vertex on next-generation immune-protection strategies.
WebsiteManufacturer of Tzield (teplizumab), the first FDA-approved therapy to delay onset of T1D in at-risk individuals. Originally developed by Provention Bio.
WebsiteUsing CRISPR gene editing to engineer insulin-producing cells that can evade the immune system without immunosuppression. Early research stage for T1D.
WebsiteDeveloping KRIYA-839, a gene therapy program aiming to restore insulin production through a one-time treatment. Currently in preclinical development.
WebsiteMaker of Dexcom G6 and G7 continuous glucose monitors (CGM), the most widely used CGM platform in the US. Dexcom CGMs form the sensor layer of most closed-loop AID systems.
WebsiteMaker of FreeStyle Libre — the world's most widely used flash CGM system. Libre 3 is a real-time CGM with 14-day wear. Abbott's technology is integral to international AID system development.
WebsiteCommunity and social signals come through official APIs, permitted feeds, embeds, or direct creator permission — never blind scraping of restricted platforms.
Stories and creator content are surfaced with consent and clear attribution. Creators control how their voice appears.
Lived experience is labeled as community or anecdotal and kept visually distinct from peer-reviewed, clinical, or regulatory items.